This paper reviews models of academic-pharmaceutical industry collaboration and debates the value of such partnerships so that those contemplating an alliance can reflect a priori on the purpose, nature and process that will provide a constructive outcome. The scope is confined to the biomedical discipline, because collaborations in other fields, such as physics and engineering, have not suffered as a result of the concerns associated with biomedicine.